2022-07-11 | NDAQ:OMCL | Press Launch

2022-07-11 | NDAQ:OMCL | Press Launch

Omnicell, Inc. (Nasdaq :OMCL), a number one supplier of treatment administration options and adherence instruments for healthcare methods and pharmacies, will launch its monetary outcomes for the second quarter 2022, after market on Thursday, August 4, 2022. The Firm will host a convention name and webcast to debate its monetary outcomes at 1:30 p.m. PT that very same day.

All events are invited to hearken to the stay name and presentation by dialing (888) 550-5424 within the U.S. or (646) 960-0819 in worldwide areas. The Convention ID is 5370673. A hyperlink to the stay and archived webcast can even be accessible on the Investor Relations part of Omnicell’s web site at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been dedicated to remodeling the pharmacy care supply mannequin to dramatically enhance outcomes and decrease prices. By way of the imaginative and prescient of the autonomous pharmacy, a mix of automation, intelligence, and technology-enabled providers, powered by a cloud information platform, Omnicell helps extra environment friendly methods to handle medicines throughout all care settings. Healthcare amenities worldwide use Omnicell automation and analytics options to assist enhance operational effectivity, scale back treatment errors, ship actionable intelligence, and enhance affected person security. Institutional and retail pharmacies throughout North America and the UK leverage Omnicell’s revolutionary treatment adherence and inhabitants well being options to enhance affected person engagement and adherence to prescriptions, serving to to scale back expensive hospital readmissions. To study extra, go to www.omnicell.com.

OMNICELL and the Omnicell brand are registered logos and Omnicell One is a trademark of Omnicell, Inc. or certainly one of its subsidiaries.

Ahead-Wanting Statements

To the extent any statements contained on this press launch cope with data that isn’t historic, these statements are “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995. With out limiting the foregoing, statements together with the phrases “anticipate,” “intend,” “could,” “will,” “ought to,” “would,” “might,” “plan,” “potential,” “anticipate,” “imagine,” “forecast,” “steerage,” “outlook,” “targets,” “goal,” “estimate,” “search,” “predict,” “venture,” and comparable expressions are meant to establish forward-looking statements. Ahead-looking statements are topic to the incidence of many occasions outdoors Omnicell’s management. Such statements embrace, however are usually not restricted to deliberate new services and the associated anticipated advantages (and any implied monetary impression), and statements about Omnicell’s technique, plans, goals, targets, and imaginative and prescient. Precise outcomes and different occasions could differ considerably from these contemplated by forward-looking statements on account of quite a few components that contain substantial identified and unknown dangers and uncertainties. These dangers and uncertainties embrace, amongst different issues, (i) dangers associated to the continuing COVID-19 pandemic (together with new variants of the virus), (ii) Omnicell’s capacity to make the most of development alternatives and develop and commercialize new options and improve present options, (iii) continued and elevated competitors from present and future opponents within the treatment administration automation options market and the treatment adherence options market, (iv) unfavorable basic financial and market circumstances or discount in demand for our options, (v) dangers associated to Omnicell’s investments in new enterprise methods or initiatives, together with its transition to promoting extra services on a subscription foundation, (vi) any disruption in Omnicell’s data know-how methods and breaches of information safety or cyber-attacks on its methods or options, (vii) Omnicell’s capacity to guard its mental property, (viii) Omnicell’s capacity to satisfy the calls for of, or keep relationships with, its institutional, retail, and specialty pharmacy prospects, (ix) dangers associated to the supply and sources of uncooked supplies and elements or worth fluctuations, shortages, or interruptions of provide, (x) Omnicell’s dependence on a restricted variety of suppliers for sure elements, gear, and uncooked supplies, in addition to applied sciences offered by third-party distributors, and (xi) different dangers and uncertainties additional described within the “Danger Components” part of Omnicell’s most up-to-date Annual Report on Type 10-Okay and subsequent quarterly stories on Type 10-Q, in addition to in Omnicell’s different stories filed with or furnished to america Securities and Change Fee (“SEC”), accessible at www.sec.gov. Ahead-looking statements needs to be thought-about in gentle of those dangers and uncertainties. Traders and others are cautioned to not place undue reliance on forward-looking statements. All forward-looking statements contained on this press launch communicate solely as of the date of this press launch. Omnicell assumes no obligation to replace any such statements publicly, or to replace the explanations precise outcomes might differ materially from these expressed or implied in any forward-looking statements, whether or not because of modified circumstances, new data, future occasions, or in any other case, besides as required by regulation.


2022-07-11 | NDAQ:OMCL | Press Launch

Leave a Reply

Your email address will not be published. Required fields are marked *